3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Testicular Neoplasms
2
Sezary Syndrome
2
Primary Myelofibrosis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pdgfra-Associated Chronic Eosinophilic Leukemia
2
Neuroblastoma
2
Myeloproliferative Disorders
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Neutrophilic, Chronic
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Hairy Cell
2
Hodgkin Disease
2
Congenital Abnormalities
2
Carcinoma, Ovarian Epithelial
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Blast Crisis
2
Interventions
Docetaxel
292
Prednisone
241
enzalutamide
195
Leuprolide
185
Radiotherapy
179
Abiraterone Acetate
170
Magnetic Resonance Spectroscopy
163
bicalutamide
141
Goserelin
138
Androgen Antagonists
121
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
108
Radiosurgery
108
apalutamide
93
abiraterone
83
gallium 68 PSMA-11
81
Specimen Handling
73
darolutamide
67
Surveys and Questionnaires
64
Gonadotropin-Releasing Hormone
63
Triptorelin Pamoate
58
Radiation
57
Biopsy
57
Brachytherapy
54
cabazitaxel
53
Standard of Care
51
Radiotherapy, Intensity-Modulated
51
Zoledronic Acid
50
pembrolizumab
49
luprolide acetate gel depot
49
Flutamide
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Ondansetron
×
Genitourinary
×
Clear all
NCT02441894
2017-01-24
PEGAZUS
Sanofi
Phase 4
Completed
21 enrolled